Page 2 - Immuno-Oncology

Bispecific antibodies have emerged as a promising class of therapeutic agents in the field of cancer immunotherapy. As of August 2023, several bispecific antibodies were in various stages of development and clinical trials, showing great potential for improving cancer treatment outcomes.

One of the most notable bispecifics is blinatumomab (Blincyto), a CD19/CD3 bispecific approved for treating acute lymphoblastic leukemia (ALL) that has demonstrated...

1. Background Study

Kidney transplantation is a surgery-based treatment for patients who have prolonged kidney failure or are suffering from chronic or end-stage kidney failure (CKD) [1]. Kidney transplant (KT) procedures in older patients rise daily [2]. The National Kidney Foundation showed that 786,000 patients are living with kidney problems, but only around 25,000 received transplants during 2021 [3]. In the...

1. Background Study

In recent times, many cancerous diseases form of uncontrolled cell division, especially non-small cell lung cancer (NSCLC), melanoma, and breast cancer. Based on statistics from the American Cancer Society, NSCLC accounts for 80% to 85% of all lung cancers [1]. Meanwhile, it is reported that the rate of affected Melanoma skin cancer is 21 per lakh per year, but it causes a significant number...

Bispecific antibodies are an emerging and promising class of targeted cancer therapies. These engineered antibodies are able to simultaneously bind to two different antigen targets, allowing for dual targeting of, for example, both a tumor cell and an immune cell (Lee et al. 2022). Over the past year, research has highlighted several key benefits of bispecific antibodies for cancer treatment.

First, bispecific antibodies enable more specific...

Recent research on the effects of the rare GAALIE mutation when present in the Fc domain of antibodies provides intriguing insights that may inform engineering of oncology therapeutics. Antibody Fc domains play a central role in eliciting anti-tumor immune responses, and customizing this region is an important strategy for enhancing cancer immunotherapy. Studies in 2023 exploring how the GAALIE mutation impacts Fc activities point to molecular mechanisms...

ichorbio is pleased to announce the release of our first list of all antibodies that are in discovery studies, preclinical and clinical trials. We're currently corresponding with as many biotech firms as we can to add their own candidates into this list. If you see that we're missing yours please contact us at [email protected] and we'll update our data immediately. 

If you'd like to get...

Updated report: Sequences from 745 antibodies and fusion proteins

Updated 15th February 2023:

In the following links you will find two spreadsheets containing antibody sequences for 745 therapeutic antibodies & fusion proteins.

We’ve created them as a resource for the scientific community – we hope that it will help you to design new and improved therapeutics at a faster rate.

Our spreadsheet includes antibody...